Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1204
Shown on this page
12
Current sort
Recently updated
Campus scope
Columbia University Irving Medical Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Columbia University Irving Medical Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 421–432 of 1,204 matching trials with a site at Columbia University Irving Medical Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 3 Interventional

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

NCT07452458
Status at this site: Recruiting
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Radiation Therapy, Temozolomide, Temporally-modulated Pulsed Radiation Therapy
Procedure · Other · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
54
States / cities
Irvine, California • Los Angeles, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

NCT05438212
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain
Interventions
Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
208
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 154 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Recruiting Phase 3 Interventional

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

NCT06708299
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
CardiolRx
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Recruiting Phase 2 Interventional

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

NCT07216391
Status at this site: Recruiting
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Antithymocyte Globulin (ATG), Teplizumab
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 34 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Active, not recruiting Phase 1 Interventional

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

NCT04227847
Site status not listed — check the official record
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
SEA-CD70, azacitidine, Venetoclax
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
47
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326
Site status not listed — check the official record
View directory record Official record
Conditions
Adenocarcinoma, Pancreatic Ductal
Interventions
Autogene cevumeran, Atezolizumab, mFOLFIRINOX
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
30
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

NCT06310031
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure
Interventions
BrioVAD System, HeartMate 3
Device
Lead sponsor
BrioHealth Solutions, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Active, not recruiting No phase listed Observational

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT06747572
Site status not listed — check the official record
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Not listed
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Recruiting No phase listed Observational

A Study of Patients With Fabry Disease (US Specific)

NCT06906367
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat HCl, ERT
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

NCT05115110
Site status not listed — check the official record
View directory record Official record
Conditions
Spinal Muscular Atrophy (SMA)
Interventions
RO7204239, Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917
Status at this site: Recruiting
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
48
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 4:04 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

NCT04340843
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 26, 2026, 4:04 AM EDT

About this Columbia University Irving Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.